Literature DB >> 30844879

Disparities Between US Opioid Overdose Deaths and Treatment Capacity: A Geospatial and Descriptive Analysis.

James R Langabeer1, Anand Gourishankar, Kimberly A Chambers, Sharmila Giri, Renita Madu, Tiffany Champagne-Langabeer.   

Abstract

INTRODUCTION: With opioid-related deaths reaching epidemic levels, gaining a better understanding of access to treatment for opioid use disorder (OUD) is critical. Most studies have focused on 1 side of the equation-either provider capacity or patients' need for care, as measured by overdose deaths. This study examines the overlay between treatment program availability and opioid mortality, comparing accessibility by region.
METHODS: Geospatial and statistical analyses were used to model OUD treatment programs relative to population density and opioid overdose death incidence at the state and county level. We computed a ratio between program capacity and mortality called the programs-per-death (PPD) ratio.
RESULTS: There were 40 274 opioid deaths in 2016 and 12 572 treatment programs across the contiguous 48 states, yielding a ratio of 1 program for every 3.2 deaths. Texas had the lowest number of treatment programs per 100 000 persons (1.4) and Maine the highest (13.2). West Virginia ranked highest in opioid deaths (39.09 per 100 000). Ohio, the District of Columbia, and West Virginia had the greatest mismatch between providers and deaths, with an average of 1 program for every 8.5 deaths. Over 32% of US counties had no treatment programs and among those with >10 deaths, nearly 2.5% had no programs. Over 19% of all counties had a ratio ≤1 provider facility per 10 deaths.
CONCLUSION: Assessing the overlay between treatment capacity and need demonstrated that regional imbalances exist. These data can aid in strategic planning to correct the mismatch and potentially reduce mortality in the most challenged geographic regions.

Entities:  

Mesh:

Year:  2019        PMID: 30844879     DOI: 10.1097/ADM.0000000000000523

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  12 in total

1.  Opioid use disorder research and the Council for the Advancement of Nursing Science priority areas.

Authors:  Patricia Eckardt; Donald Bailey; Holli A DeVon; Cynthia Dougherty; Pamela Ginex; Cheryl A Krause-Parello; Rita H Pickler; Therese S Richmond; Eleanor Rivera; Carol F Roye; Nancy Redeker
Journal:  Nurs Outlook       Date:  2020-04-09       Impact factor: 3.250

2.  Green Hope: Perspectives on Cannabis from People who Use Opioids.

Authors:  Miriam Boeri; Elise Pereira; Alina Minkova; Kevin Marcato; Elianne Martinez; Denise Woodall
Journal:  Sociol Inq       Date:  2020-02-13

Review 3.  Changing Outdated Methadone Regulations That Harm Pregnant Patients.

Authors:  John J McCarthy; Hendree E Jones; Mishka Terplan; Vania P Rudolf; Melinda Campopiano von Klimo
Journal:  J Addict Med       Date:  2021-04-01       Impact factor: 3.702

4.  Data quality considerations when using county-level opioid overdose death rates to inform policy and practice.

Authors:  Christopher M Jones; Margaret Warner; Holly Hedegaard; Wilson Compton
Journal:  Drug Alcohol Depend       Date:  2019-08-30       Impact factor: 4.852

5.  Alternatives to Arrest for Illicit Opioid Use: A Joint Criminal Justice and Healthcare Treatment Collaboration.

Authors:  Andrea J Yatsco; Rachel D Garza; Tiffany Champagne-Langabeer; James R Langabeer
Journal:  Subst Abuse       Date:  2020-08-31

6.  Feasibility and outcomes from an integrated bridge treatment program for opioid use disorder.

Authors:  James R Langabeer; Tiffany Champagne-Langabeer; Andrea J Yatsco; Meredith M O'Neal; Marylou Cardenas-Turanzas; Samuel Prater; Samuel Luber; Angela Stotts; Tom Fadial; Gina Khraish; Henry Wang; Bentley J Bobrow; Kimberly A Chambers
Journal:  J Am Coll Emerg Physicians Open       Date:  2021-03-31

7.  Demystifying the Dark Web Opioid Trade: Content Analysis on Anonymous Market Listings and Forum Posts.

Authors:  Zhengyi Li; Xiangyu Du; Xiaojing Liao; Xiaoqian Jiang; Tiffany Champagne-Langabeer
Journal:  J Med Internet Res       Date:  2021-02-17       Impact factor: 5.428

Review 8.  Routes of non-traditional entry into buprenorphine treatment programs.

Authors:  Tiffany Champagne-Langabeer; Michael W Swank; James R Langabeer
Journal:  Subst Abuse Treat Prev Policy       Date:  2020-01-20

9.  Social vulnerability in persons with chronic hepatitis C virus infection is associated with a higher risk of prescription opioid use.

Authors:  Adeel A Butt; Peng Yan; Shashi Kapadia; Abdul-Badi Abou-Samra; Naveed Z Janjua; Said Ibrahim
Journal:  Sci Rep       Date:  2021-03-15       Impact factor: 4.379

10.  Sociodemographic and Clinical Characteristics Associated with Improvements in Quality of Life for Participants with Opioid Use Disorder.

Authors:  Assaf Gottlieb; Christine Bakos-Block; James R Langabeer; Tiffany Champagne-Langabeer
Journal:  Healthcare (Basel)       Date:  2022-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.